Stephen R. Knight
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score
Knight, Stephen R.; Ho, Antonia; Pius, Riinu; Buchan, Iain; Carson, Gail; Drake, Thomas M.; Dunning, Jake; Fairfield, Cameron J.; Gamble, Carrol; Green, Christopher A.; Gupta, Rishi K.; Halpin, Sophie; Hardwick, Hayley; Holden, Karl; Horby, Peter W.; Jackson, Clare; McLean, Kenneth A.; Merson, Laura; Nguyen-Van-Tam, Jonathan S.; Norman, Lisa; Noursadeghi, Mahdad; Olliaro, Piero L.; Pritchard, Mark G.; Russell, Clark D.; Shaw, Catherine A.; Sheikh, Aziz; Solomon, Tom; Sudlow, Cathie; Swann, Olivia V.; Turtle, Lance; Openshaw, Peter J.M.; Baillie, J. Kenneth; Semple, Malcolm Gracie; Docherty, Annemarie B.; Harrison, Ewen M.
Authors
Antonia Ho
Riinu Pius
Iain Buchan
Gail Carson
Thomas M. Drake
Jake Dunning
Cameron J. Fairfield
Carrol Gamble
Christopher A. Green
Rishi K. Gupta
Sophie Halpin
Hayley Hardwick
Karl Holden
Peter W. Horby
Clare Jackson
Kenneth A. McLean
Laura Merson
JONATHAN NGUYEN-VAN-TAM Jonathan.Nguyen-Van-tam1@nottingham.ac.uk
Senior Strategy Adviser
Lisa Norman
Mahdad Noursadeghi
Piero L. Olliaro
Mark G. Pritchard
Clark D. Russell
Catherine A. Shaw
Aziz Sheikh
Tom Solomon
Cathie Sudlow
Olivia V. Swann
Lance Turtle
Peter J.M. Openshaw
J. Kenneth Baillie
Malcolm Gracie Semple
Annemarie B. Docherty
Ewen M. Harrison
Abstract
Objectives To develop and validate a pragmatic risk score to predict mortality for patients admitted to hospital with covid-19. Design Prospective observational cohort study: ISARIC WHO CCP-UK study (ISARIC Coronavirus Clinical Characterisation Consortium [4C]). Model training was performed on a cohort of patients recruited between 6 February and 20 May 2020, with validation conducted on a second cohort of patients recruited between 21 May and 29 June 2020. Setting 260 hospitals across England, Scotland, and Wales. Participants Adult patients (?18 years) admitted to hospital with covid-19 admitted at least four weeks before final data extraction. Main outcome measures In-hospital mortality. Results There were 34 692 patients included in the derivation dataset (mortality rate 31.7%) and 22 454 in the validation dataset (mortality 31.5%). The final 4C Mortality Score included eight variables readily available at initial hospital assessment: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness, urea, and C-reactive protein (score range 0-21 points). The 4C risk stratification score demonstrated high discrimination for mortality (derivation cohort: AUROC 0.79; 95% CI 0.78 - 0.79; validation cohort 0.78, 0.77-0.79) with excellent calibration (slope = 1.0). Patients with a score ?15 (n = 2310, 17.4%) had a 67% mortality (i.e., positive predictive value 67%) compared with 1.0% mortality for those with a score ?3 (n = 918, 7%; negative predictive value 99%). Discriminatory performance was higher than 15 pre-existing risk stratification scores (AUROC range 0.60-0.76), with scores developed in other covid-19 cohorts often performing poorly (range 0.63-0.73). Conclusions We have developed and validated an easy-to-use risk stratification score based on commonly available parameters at hospital presentation. This outperformed existing scores, demonstrated utility to directly inform clinical decision making, and can be used to stratify inpatients with covid-19 into different management groups. The 4C Mortality Score may help clinicians identify patients with covid-19 at high risk of dying during current and subsequent waves of the pandemic.
Other Type | Other |
---|---|
Deposit Date | Sep 27, 2020 |
Publicly Available Date | Oct 6, 2020 |
DOI | https://doi.org/10.1101/2020.07.30.20165464 |
Public URL | https://nottingham-repository.worktribe.com/output/4816439 |
Related Public URLs | https://www.medrxiv.org/content/10.1101/2020.07.30.20165464v1 |
Files
Risk stratification of patients
(1.2 Mb)
PDF
Licence
No License Set (All rights reserved)
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
You might also like
Molnupiravir for SARS-CoV-2 infection: Public health and policy implications
(2023)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search